This analysis examines Dr Lal PathLabs (LALPATHLAB) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Lal PathLabs Revenue Trend
The top line tells a positive story: Dr Lal PathLabs's revenue advanced 12.2% to ₹2,763 Cr in FY2026.
Over the past 10 years, revenue has grown at a healthy 13.3% CAGR, from ₹791 Cr to ₹2,763 Cr. That's solid, above-average growth.
At ₹2,763 Cr in annual revenue, Dr Lal PathLabs is one of the mid-sized players in the healthcare space.
Revenue has moved in the same direction for 3 years running, suggesting the growth trend has structural legs.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹2,763 Cr | +12.2% |
| FY2025 | ₹2,461 Cr | +10.5% |
| FY2024 | ₹2,227 Cr | +10.4% |
| FY2023 | ₹2,017 Cr | -3.4% |
| FY2022 | ₹2,087 Cr | — |
View Dr Lal PathLabs's full 10-year revenue trend with CAGR analysis →
Lal PathLabs Profitability
Net profit reached ₹510 Cr in FY2026, up 4.7% from ₹487 Cr in FY2025.
Margins came under pressure in FY2026, with net profit margin dropping to 18.5% from 19.8%.
The diluted EPS figure moved up to ₹30.20 in FY2026, against ₹29.20 posted in FY2025.
Is Lal PathLabs Undervalued
Dr Lal PathLabs shares are currently trading at ₹1,900.40.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Lal PathLabs Shareholding Pattern
At 53.2%, the promoter stake has been flat for the past 4 quarters.
FII ownership stands at 17.4%, down from the 21.9% recorded a year ago.
Domestic institutions moved their stake up to 21.6% from 18.5% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 53.2% | 17.4% | 21.6% | 7.5% |
| Mar 2026 | 53.2% | 17.2% | 21.4% | 7.9% |
| Dec 2025 | 53.2% | 20.3% | 19.2% | 6.9% |
| Sep 2025 | 53.2% | 21.9% | 18.5% | 6.1% |
Track quarterly shareholding changes for Dr Lal PathLabs →
Lal PathLabs Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹31.46B at the end of FY2026, up 15.8% from ₹27.17B a year earlier.
Other Assets is the largest block at 39.3%, followed by Intangibles & Goodwill at 23.5% and Cash & ST Investments at 21.2%.
Equity makes up 80.8% of liabilities and equity, with debt at 6.3% and operating liabilities at 12.9%. Over the year, debt is up 26.4% and equity is up 15.2%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 6.65B |
| Receivables | 1.11B |
| Inventories | 438.55M |
| Property, Plant & Equipment | 3.48B |
| Intangibles & Goodwill | 7.41B |
| Other Assets | 12.37B |
| Category | Value |
|---|---|
| Equity | 25.41B |
| Short-term Debt | 535.74M |
| Long-term Debt | 1.45B |
| Trade Payables | 1.81B |
| Other Liabilities | 2.25B |
Lal PathLabs Key Takeaways
Here's the bottom line on Dr Lal PathLabs (LALPATHLAB) based on the latest available financials.
Revenue of ₹2,763 Cr in FY2026, up 12.2% year-over-year.
Long-term revenue has been compounding at 13.3% annually over 10 years.
The company is profitable, with a net margin of 18.5% and net income of ₹510 Cr.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Dr Lal PathLabs's detailed profile on Craytheon.